粉样β和多巴胺消耗对 perfusion 和临床症状的影响
Young-Gun Lee1,2, Seun Jeon1,3,4, Sung Woo Kang1
1Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.
概括
粉样β和多巴胺基耗尽会影响阿尔茨海默病 (AD) 和勒维体痴呆症 (DLB) 中的大脑输液和认知. 这些病理影响区域血流,这反过来影响临床症状和认知功能.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 放射学 放射学是一门学科.
背景情况:
- 在阿尔茨海默氏症 (AD) 和患有莱维体 (DLB) 的痴呆症中,混合病理很常见.
- 在这些条件下,粉样β沉积,多巴胺基耗尽和脑 perfusion 之间的相互作用仍然不清楚.
研究的目的:
- 为了研究粉样β和多巴胺基耗尽对AD和/或DLB患者的大脑输液和临床症状的影响.
- 阐明正电子发射断层扫描 (PET) 影像标记物与区域大脑血流之间的关系.
主要方法:
- 99名患有认知障碍 (AD和/或DLB) 的患者和32名对照人接受了18F-florbetaben (FBB) 和双相多巴胺载体 (DAT) PET扫描.
- 测量包括FBB标准化吸收值比率 (SUVR),条纹DAT吸收量和脑 perfusion.
- 分析了PET发现,输液模式和临床症状之间的相关性.
主要成果:
- 较高的FBB-SUVR (粉样β沉积) 和较低的腹腔条纹性DAT吸收 (多巴胺消耗) 相互关联.
- 粉样蛋白β沉积与左侧内腔/腔-双侧区域的低 perfusion 相关.
- 多巴氨基耗尽与/海马区域的高 perfusion 相关.
结论:
- 粉样β沉积和多巴胺基耗尽显著影响区域大脑输液.
- 区域性输液变化调解了这些病理对临床症状和认知功能的影响.
- 这些发现有助于了解AD和DLB的正常衰老和认知障碍的范围.
相关概念视频
Alzheimer's Disease: Overview
527
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
527
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220
Parkinson's Disease: Overview
606
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
606
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302


